Email Updates

Search form

You are here

SABES

Status
Ongoing
Phase
IV
Principal Investigator(s)
Ann Duerr
Objective

HOME: a comprehensive HIV testing and linkage package for young MSM of color.

Effect of rapid ART (Atripla) after HIV infection on HIV viral load.

Prevention Option(s)
Treatment
Study Design
Controlled
Randomized
Arms and Assigned Interventions
Description
Immediate ART (Atripla) Daily Atripla will be provided to these patients for the duration of the study beginning at enrollment.
ARMs
Experimental
Description
Deferred ART (Atripla) Daily Atripla will be provided to these patients for the duration of the study beginning at 24 weeks.
ARMs
Placebo Comparator
Trial Sponsors
Fred Hutchinson Cancer Research Center
July 2013
December 2016
Enrollment
150
18
Years
Population
MSM
Sites

Asociación Civil Impacta Salud y Educación

Lima
Peru